Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

FDA DTC Guidance - Presenting Quantitative Efficacy and Risk Information

FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.

21 U.S.C. 352(n); 21 CFR 202.1(e)(5)-(6); FDA Quantitative Efficacy and Risk DTC Guidance (2023)

FDA Draft Guidance - Character-Space-Limited Platforms

On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)

FDA Guidance - Communications Consistent with FDA-Required Labeling (CFL)

Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6); FDA CFL Q&A Guidance (2018)

FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner

Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.

21 CFR 202.1(e)(1); 21 U.S.C. 352(n)

FDA Rx DTC Print and Digital Ads - Brief Summary of Risks

Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.

21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(3)(iii), (e)(5)-(6)

FDA Rx Promotion - Comparative and Uniqueness Claims

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)

FDA Rx Promotion - Fair Balance of Benefit and Risk

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.

21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)

FDA Rx Promotion - Proprietary and Established Name Presentation

Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.

21 CFR 202.1(b)(1)-(3); 21 CFR 201.10(g); FDA Product Name Placement Guidance (2017)

FDA Rx Promotion - Safety Claims and Risk Minimization

Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(7)

FDA Rx Promotion - Use Limited to Approved Indications

Prescription drug and biologic promotion may not recommend or suggest any population, dose, regimen, timing or combination that is not in the approved labeling.

21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4), (e)(5), (e)(6)

FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.

FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)

Browse by category

Browse by jurisdiction

Browse by regulator